ALKS 4230-007/GOG-3063/ENGOT-ov68: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian

The purpose of this study is to find answers to the following research questions: • How effective is nemvaleukin alone and in combination with Pembrolizumab in treating your epithelial ovarian, fallopian tube, or primary peritoneal cancer compared with chemotherapy? • What effect does nemvaleukin alone and in combination with Pembrolizumab have on your body and epithelial ovarian, fallopian tube, or primary peritoneal cancer? • What effect does nemvaleukin in combination with Pembrolizumab have on your overall health and well-being? • How does nemvaleukin in combination with Pembrolizumab move through the body? • Is nemvaleukin in combination with Pembrolizumab safe and well tolerated in subjects with epithelial ovarian, fallopian tube, or primary peritoneal cancer as compared to chemotherapy?

Are you Eligible? (Inclusion Criteria)

• diagnosed with epithelial ovarian, primary peritoneal, or fallopian tube cancers 2. must have had atleast one line but not more than 5 lines of treatment or chemotherapy. 3. at least one measurable lesion on scans. 4. must have tissue available from previous surgery or willing to have a biopsy